JOIN OUR SCIENTIFIC LEADERSHIP AT CPHI MILAN 2026.Advance Your Molecule’s Journey from Concept to Commercialization
Meet Us at CPHI Milan 2026 | Oct 06–08, 2026 Milan
Today’s pharma innovators face growing complexity across therapeutic modalities, timelines, regulatory demands, and supply chain resilience. Aragen delivers end-to-end CRDMO solutions for small molecules, biologics, peptides, oligonucleotides, ADCs, and next-generation therapeutics—with integrated discovery, development, manufacturing, and analytical capabilities that ensure a seamless path from early research to commercial supply
Powered by deep scientific expertise, advanced infrastructure, and Digital & AI-enabled insights, we deliver with a steadfast commitment to quality, sustainability, and supply chain resilience to bring life-changing therapies to patients faster.
Small Molecules—Process Design to Commercial Supply
End-to-end support from route selection and process optimization to seamless tech transfer, analytical development, clinical supply, commercial manufacturing, and lifecycle management.
Large Molecules—Cell Line to cGMP Supply
An integrated biologics platform spanning cell line development, process characterization, manufacturing scale-up, and regulatory readiness for mAbs, biosimilars, bispecifics, and other complex biologics — without losing momentum.
Emerging Modalities
